

**REMARKS**

Claims 20-30 have been canceled, without prejudice, as being directed to a non-elected invention.

In the Office Action mailed July 27, 2004, the Examiner restricted the claims into Groups I-VI. Applicant elects the claims of Group I. As a species of peptide, Applicant elects the peptide Phe-Gly-Leu-Met-NH<sub>2</sub> set forth in SEQ ID NO:2. Further, as a species of physiological disorder, Applicant elects preeclampsia. Claims 1-6 and 19 read on this peptide and physiological disorder. The above election is made without traverse.

In the Office Action, Examiner states as his reason for restriction of Groups I and II that "the antibody of Invention II could be used to identify novel tachykinins that contain the specified amino acid sequence." Applicant urges that one skilled in the art would recognize that a monoclonal antibody generated to the indicated peptides could be used to distinguish the peptides from such novel tachykinins. Further, as regards Examiner's assertion in his reasoning for restriction between Groups II and V that the claims thereof "are different products that recognize different molecules", Applicant wishes to clarify that the peptides specifically bound by the monoclonal antibodies of Group II claims are examples of substances which promote binding of tightly bound magnesium, as claimed in the claim of Group V.

Respectfully submitted,

By:

  
Nancy T. Morris, Reg. No. 42,017  
STINSON MORRISON HECKER LLP  
1201 Walnut Street, Suite 2800  
Kansas City, MO 64106-2150  
Telephone: (816) 842-8600  
Facsimile: (816) 691-3495  
Attorney for Applicant(s)